ATAI

MKT CAP:$873M

Atai Beckley N.V

Market Cap

$873M

Healthcare·Medical - Pharmaceuticals·🇳🇱 Netherlands·NASDAQ

Healthcare·Medical·🇳🇱·NASDAQ

Stock Price

$4.71+$0.84 (+21.71%)

Apr 22, 2026

Company Details

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is...

CEO

Srinivas G. Rao

IPO Date

Jun 18, 2021

Website

www.ataibeckley.com

Key Metrics TTM

Revenue

$3M

— YoY

Net Income

-$154M

EPS (Diluted)

-$0.81

Free Cash Flow

-$90M

Revenue / Share

$0.01

Gross Margin

-259.1%

Operating Margin

-3457.4%

Net Margin

-5109.1%

FCF Margin

-2993.3%

P/S

289.4x

P/E

—

Earnings Reports

Q4 2025

May 13, 2026

PENDING

FY 2025

Nov 12, 2025

$3M+881.5%EPS -$0.57

Q3 2025

Nov 12, 2025

$749.0K+1772.5%EPS -$0.28

Q2 2025

Aug 14, 2025

$719.0K+163.4%EPS -$0.14

Q1 2025

May 14, 2025

$2MEPS -$0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$0	$0	-$7M
Q2 24	$273.0K	$273.0K	-$26M
Q3 24	$40.0K	$40.0K	-$23M
Q4 24	-$5.0K	-$5.0K	-$30M
Q1 25	$2M	-$9M	-$20M
Q2 25	$719.0K	$719.0K	-$25M
Q3 25	$749.0K	$749.0K	-$28M

Valuation

Quarter	P/S	P/E
Q3 20	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	2835.5x	—
Q1 25	468.8x	—
Q2 25	378.2x	—
Q3 25	289.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	-$5M	-$5M
Q2 24	-$16M	-$16M
Q3 24	-$19M	-$19M
Q4 24	-$24M	-$24M
Q1 25	-$18M	-$18M
Q2 25	-$14M	-$19M
Q3 25	-$23M	-$29M

Capital Expenditures

Quarter	CapEx
Q3 20	$1.0K
Q2 24	$4
Q3 24	$1.0K
Q4 24	$89.0K
Q1 25	$268.0K
Q2 25	$5M
Q3 25	$5M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 25	—	+196.8%
Q2 25	+163.4%	-0.0%
Q3 25	+1772.5%	+28.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$2M	—
Q2 24	$0	0.0%
Q3 24	$5M	12615.0%
Q4 24	$8M	—
Q1 25	$3M	215.8%
Q2 25	$3M	373.6%
Q3 25	$3M	439.7%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 20	$3M	$4M	—
Q2 24	$13M	$13M	—
Q3 24	$12M	$10M	—
Q4 24	$19M	$11M	—
Q1 25	$11M	$10M	$234.0K
Q2 25	$11M	$15M	—
Q3 25	$15M	$15M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$362M	$0	$362M
Q1 22	$124M	$211M	$335M
Q2 22	$84M	$228M	$312M
Q3 22	$143M	$162M	$304M
Q4 22	$191M	$82M	$273M
Q1 23	$186M	$64M	$250M
Q2 23	$141M	$86M	$227M
Q3 23	$76M	$133M	$209M
Q4 23	$45M	$134M	$179M
Q1 24	$19M	$87M	$106M
Q2 24	$19M	$69M	$88M
Q3 24	$30M	$56M	$86M
Q4 24	$18M	$45M	$62M
Q1 25	$48M	$50M	$98M
Q2 25	$62M	$34M	$96M
Q3 25	$30M	$84M	$115M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	153M	—	—
Q2 24	160M	+5.1%	—
Q3 24	161M	+0.1%	—
Q4 24	160M	-0.3%	—
Q1 25	176M	+10.1%	+15.5%
Q2 25	197M	+11.5%	+22.6%
Q3 25	218M	+10.7%	+35.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	—	—
Q2 24	$3.3K	83
Q3 24	$482	83
Q4 24	-$93	54
Q1 25	$28.8K	54
Q2 25	$13.3K	54
Q3 25	$13.9K	54

Revenue / Employee